

β^1 cont.

nalbuphine, thebaine, levallorphan, oxymorphone, butorphanol, buprenorphine, levorphanol, meptazinol, pentazocine, dezocine, and their pharmacologically effective esters and salts, and an effective amount of an antidepressant, which antidepressant is selected from the group consisting of imipramine, amitriptyline, trimipramine, doxepin, desipramine, nortriptyline, protriptyline, amoxapine, clomipramine, maprotiline, and carbamazepine and bupropion, sertraline, fluoxetine, trazodone, and their pharmacologically effective esters and salts.

β^2

16. The pharmaceutical composition according to claim 15 wherein the antidepressant is fluoxetine in an amount of 20-80 mg.

17. The pharmaceutical composition according to claims 15 wherein the antidepressant is fluoxetine in an amount of fluoxetine is 10-40 mg.

β^3

21. A drug combination comprising an effective pharmaceutical amount of an opioid antagnoist selected from the group consisting of nalmefene, naltrexone, nalmefene, nalorphine, nalbuphine, thebaine, levallorphan, oxymorphone, butorphanol, buprenorphine, levorphanol, meptazinol, pentazocine, dezocine, and their pharmacologically, effective esters and salts, and an effective pharmacentral amount of an antidepressant, which antidepressant is selected from the group consisting of imipramine, amitriptyline, trimipramine, doxepin, desipramine, nortriptyline, protriptyline, amoxapine, clomipramine, maprotiline, and carbamazepine and bupropion, sertraline, fluoxetine, trazodone, and their pharmacologically effective esters and salts.

22. The drug combination according to claim 21 wherein an opioid antagonist is naltrexone present in an amount of 10-150 mg.

23. The drug combination according to claim 22 wherein the antidepressant is fluoxetine present in the amount of 20-80 mg.

B³ cont.
24. The drug combination according to claim 22 wherein the antidepressant is fluoxetine present in more than one dosage, each dosage having an amount of 10-40 mg.

25. The drug combination according to claim 21 wherein the opioid antagoist is naltrexone present in the amount of 10-25 mg, and the antidepressant is fluoxetine present in the amount less than 20 mg.

B⁴
26. A drug treatment regiment comprising an effective pharmaceutical amount of an opioid antagoist selected from the group consisting of nalmefene, naltrexone, nalmefene, nalorphine, nalbuphine, thebaine, levallorphan, oxymorphone, butorphanol, buprenorphine, levorphanol, meptazinol, pentazocine, dezocine, and their pharmacologically, effective esters and salts, and an effective pharmacentral amount of an antidepressant, which antidepressant is selected from the group consisting of imipramine, amitriptyline, trimipramine, doxepin, desipramine, nortriptyline, protriptyline, amoxapine, clomipramine, maprotiline, and carbamazepine and bupropion, sertraline, fluoxetine, trazodone, and their pharmacologically effective esters and salts.

27. The drug treatment regiment according to claim 26 wherein an opioid antagonist is naltrexone present in an amount of 10-150 mg.

28. The drug treatment regiment according to claim 27 wherein the antidepressant is fluoxetine present in the amount of 20-80 mg.

29. The drug treatment regiment according to claim 27 wherein the antidepressant is fluoxetine present in more than one dosage, each dosage having an amount of 10-40 mg.